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Abstract
Background: A hallmark of prion disease is the transformation of normal cellular prion protein
(PrPc) into an infectious disease-associated isoform, (PrPsc). Anti-prion protein monoclonal
antibodies are invaluable for structure-function studies of PrP molecules. Furthermore recent in
vitro and in vivo studies indicate that anti-PrP monoclonal antibodies can prevent the incorporation
of PrPc into propagating prions.
In the present article, we show two new human phage antibodies, isolated on recombinant hamster
prion protein (rHaPrP).
Results: We adopted an antibody phage display strategy to isolate specific human antibodies
directed towards rHaPrP which has been used as a bait for panning the synthetic ETH-2 antibody
phage library. Two phage antibodies clones named MA3.B4 and MA3.G3 were isolated and
characterized under genetic biochemical and immunocytochemical aspects. The clones were found
to recognize the prion protein in ELISA studies. In flow-cytometry studies, these human single chain
Fragment variable (scFv) phage-antibodies show a well defined pattern of reactivity on human
lymphoblastoid and myeloid cells.
Conclusion: Sequence analysis of the gene encoding for the antibody fragments and antigen
recognition patterns determined by flow-cytometry analysis indicate that the isolated scFvs
recognize novel epitopes in the PrPc molecule. These new anti PrPc human antibodies are unique
reagents for prion protein detection and may represent a biologic platform to develop new
reagents to treat PrPsc associated disease.
Background
The disease-associated PrPsc or transmissible spongiform
encephalopathies (TSEs), are invariably lethal neurode-
generative illnesses that affect humans and many animal
species; they include bovine spongiform encephalopathy
of cattle and Creutzfeldt-Jakob disease (CJD) in humans
[1,2]. The causative agent is termed prion and was pro-
posed to be identical to PrPsc, a pathological conformer of
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the PrPc encoded by the Prnp gene [1]. The conversion of
the normal PrPc into the abnormal PrPsc isoform is a key
feature of prion diseases [3]. Although the molecular
mechanisms of conversion are not fully understood, it is
known that mature PrPc expressed on the cell surface is
essential for prion propagation and pathogenesis. Con-
version of PrPc to PrPsc is believed to involve direct inter-
action of the two prion protein (PrP) isoforms [3,4].
Several agents including anti-PrP monoclonal antibodies
(mAbs) have been directed at the binding of the two PrP
isoforms to inhibit the conversion of PrPc to PrPsc and
ultimately block the neuronal pathogenicity [5,6]. How-
ever, the administration of monoclonal antibodies (mAb)
generated via hybridoma technology while feasible and
effective present several limitations [7]. The 145–150 kDa
IgG protein is poorly diffused from vessels into tissues,
particularly into the central nervous tissue. This may
explain why administration of mAbs has been shown to
prevent prion pathogenesis only when administred simul-
taneously or shortly after peripheral prion infection [6]. It
has been also reported that intracerebral injection of anti-
PrP IgG antibodies provoked neurotoxicity by cross-link-
ing PrPc [8]. Moreover, the treatment of human patients
with rodent monoclonal antibodies is limited by the
severe adverse effects due to its xenogenic origin [7].
Recombinant human antibody fragments, may represent
an effective alternative for immunotherapy of TSEs [9].
Recently, by applying a biopanning-based approach, we
were able to select from the ETH-2 library human scFv
phage antibodies specifically recognizing the pathological
isoform of the hamster prion protein showing transcura-
ble affinity for the PrPc expressed on human cells [10].
In the present article, we describe new reactive human
phage antibodies with a well defined pattern of reactivity
on human cell lines. These phage antibodies were isolated
using an identical bioapanning-based strategy with
rHaPrP as a bait.
The antibody fragments retain the targeting specificity of
the whole IgG mAbs but can be produced less expensively
and possess other unique and superior properties for diag-
nostic and therapeutic applications [11].
Results and Discussion
Phage antibody selection
To isolate phage antibodies specific for PrP protein, an
aliquot of the human synthetic ETH-2 library containing
approximately 1 × 1012 cfu phages was introduced for
panning into Maxisorp immunotubes coated with
rHaPrP. Nonspecifically absorbed phages were removed
by intensive washing. Specific bound phages were eluted,
amplified and used for next round of selection as
described [12]. The isolated phage populations were
tested in ELISA and flow-cytometry after each step of bio-
panning. Figure 1 shows that the binding level of polyclo-
nal phage antibodies with rHaPrP and living/intact CCRF-
CEM cells parallels with the progression of biopanning
selections.
Phage antibody selection and molecular genetics characteri- zation Figure 1
Phage antibody selection and molecular genetics 
characterization. In the upper part of the figure (panels A, 
B, C and D) the FACS binding profiles of the ETH-2 library 
and selected phage antibody populations with CCRF-CEM 
cells are shown after each round of biopanning selection. In 
the inserted boxes, the ELISA reactivity of the ETH-2 library 
(A') and selected phage antibody populations (B', C', D') with 
the rHaPrP are shown in parallel with the irrelevant phage 
antibody anti glucose oxidase and anti tetanus toxoid (A", B", 
C" and D"). Experiments were repeated at least twice and 
mean ± SD from representative experiments (triplicate sam-
ples) is shown. The cut-off value separating positive from 
negative sample was calculated as 3 standard deviation above 
the mean of the value obtained from irrelevant phage anti-
bodies (0,085 OD). In the lower part of the figure, the nucle-
otide composition and the corresponding amino acid 
sequences in the CDR3 regions of the selected scFv antibod-
ies MA3.B4 and MA3.G3 are shown. A schematic representa-
tion of the scFv antibody gene as M13 pIII fusion protein is 
also illustrated.
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Phage antibody characterization
After the third round of panning, polyclonal phage anti-
bodies were amplified in TG1 E. coli bacteria and single
colonies were picked-up and tested for rHaPrP recogni-
tion in ELISA. Two of the most reactive clones named
MA3.B4 and MA3.G3 were isolated and further character-
ized. Molecular-genetics analysis shows that the scFvs
MA3.G3 and MA3.B4 displayed on M13 phage are
encoded by two different CDR3 sequences (Fig. 1) and
that scFvs displayed on phages are intact molecules of 27
kDa (data not shown). Therefore, we tested the PrPc spe-
cificity of the phage antibodies verifying their reactivity
with hamster brain omogenates in parallel with the irrel-
evant phage antibodies anti glucose oxidase and anti teta-
nus toxoid. As shown in figure 2A, the phage antibodies
MA3.B4 and MA3.G3 both react with rHaPrp and hamster
brain homogenates.
To eliminate concerns about specificity of the phage anti-
bodies we utilized the cell-type specific extinction of PrPc
in granulocyte differentiation that can be recapitulated in
vitro by all-trans retinoic acid (ATRA) treatment of HL-60
cells [13]. Flow-cytometry was performed in order to
assess a possible relationship between the down-regula-
tion of surface PrPc and antibody staining. HL-60 cells
were treated with ATRA for 72 hrs and stained either with
the phage antibodies or with the rodent mAb 3F4. The fig-
ure 2B shows a decrease in membrane of prion protein
expression in HL-60 cells treated with ATRA vs untreated
cells when staining is performed with the mAb 3F4 or the
phage antibodies MA3.B4 and MA3.G3.
PrPc typing on human cells
PrPc expression was examined with phage antibodies and
mAb 3F4 on numerous human cell lines which include
lymphobastoid and myeloid cells, the neuroblastoma cell
line SK-N-BE, and resting or activated PBMC. As it is
shown in figure 3, the staining of the phage antibodies
MA3.B4 and MA3.G3 show a well defined reactivity pat-
tern.
The phage antibodies are reactive on CCRF-CEM, Jurkat,
H9, RPMI 8226, and HL60 cell lines. When compared
with the Mab 3F4, the binding of phage antibodies is sig-
nificantly different in Nalm-6 and THP-1 cell lines, that
react poorly or not at all with the phage antibodies. The
phage antibody MA3.B4 is unable to detect PrPc on the
SK-N-BE cell line. Furthermore the two phage antibodies
show different reactivity on resting and activated human
PBMC. Particularly MA3.G3 shows increased staining on
PHA-activated human PBMC in respect to resting PBMC
according to results previously reported [14].
These pattern of immunoreactivity may be due to the high
molecular heterogeneity of PrPc that only for some
Phage antibody specificity Figure 2
Phage antibody specificity. In the panel A, the mono-
clonal phage antibodies MA3.G3 and MA3.B4 are analyzed by 
ELISA for rHaPrP and brain homogenates recognition. As 
controls the irrelevant phage antibody anti glucose oxidase 
and anti tetanus toxoid are also shown. Experiments were 
repeated at least twice and mean ± SD from representative 
experiments (triplicate samples) is shown. The cut-off value 
separating positive from negative sample was calculated as 3 
standard deviation above the mean of the value obtained 
from irrelevant phage antibodies (0,086 OD for rHaPrp, 
0,052 OD for brain homogenate). In panel B, the monoclonal 
phage antibodies and the rodent mAb 3F4 were tested in 
flow-cytometry on human HL-60 cells. The surface PrPc 
expression was down-regulated by ATRA inducing granulo-
cytic differentiation. HL-60 cells were cultured in the pres-
ence of 1 µM ATRA for 1 and 3 days, then stained for flow 
cytometry analysis with scFvs MA3.B4, MA3.G3 and mAb 
3F4. Basal level of PrPc staining in undifferentiated cells (solid 
line) is shown relative to an irrelevant phage antibody, spe-
cific for glucose oxidase, or an IgG2b isotype control (in 
gray). The progressive decrease of PrPc staining during differ-
entiation is shown in black.
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epitopes may be mimicked by the three dimensional
structure of the recombinant PrP expressed by E. coli.
Infact, extensive biochemical characterizations conducted
with panel of mAbs have demonstrated the molecular
complexity of PrPc proteins. Over 50 biochemical forms
each representing a distinct PrPc species based on combi-
nations of different molecular weights and isoelectric
points (pIs) have been identified by 2-D immunoblot
spots [15]. Moreover previously reported data have shown
that monoclonal antibodies raised against recombinant
human prion protein folded into alpha or beta conforma-
tions exhibit striking heterogeneity in their specificity for
truncations and glycoforms of mouse brain PrPc [16]. So
It may be that one epitopes not present or buried on SK-
N-BE, THP1 and Nalm 6 cell lines has been intercepted by
the phage antibody MA3.B4 or MA3.G3 selected with
rHaPrP as a bait.
Collectively these data suggest that the two phage anti-
bodies do not recognize the same epitope when compared
with the rodent mAb 3F4, and the binding properties of
the newly isolated scFvs appear to be novel. Furthermore
the phage antibodies do not react in Western blot analysis
conducted with various prion protein preparations, prob-
ably for conformational structure of the target epitope
(data not shown). Finally, MA3.B4 phage antibody
appears very suitable in PrPc detection in immunocyto-
chemical analysis (Fig. 4).
By summing up our data we can conclude that the human
antibodies we isolated and characterized, are the first
human phage antibodies in scFv format recognizing the
prion protein expressed on the cell membrane of human
cells. In fact, previously characterized human phage anti-
bodies have not been tested on prion proteins expressed
by viable human cells [17]. Furthermore phage antibodies
isolated using the pathological isoform of the hamster
prion protein as a bait do not react in ELISA with rHaPrP,
and show transcurable reactivity with PrPc on CCRF-CEM
cells, indicating that the two classes of phage antibodies
recognize distinct epitopes in the prion protein [10].
Conclusion
Several reports indicate that humoral immune responses
against the prion protein can antagonize prion infections
[6,18,19]. This is true even when such responses are
Immunocytochemical detection Figure 4
Immunocytochemical detection. The immunocyto-
chemical detection of PrP on CCRF-CEM cells with the 
phage antibody MA3.B4 is shown. In A and B the immunos-
taining at two different magnification, in C and D the reactiv-
ity of CCRF-CEM cells with two distinct irrelevant phage 
antibodies (anti glucose oxidase and anti tetanus toxoid, 
respectively) are shown.
A B
C D
Flow-cytometry detection Figure 3
Flow-cytometry detection. High representative flow-
cytometry profiles of the phage antibodies MA3.G3, MA3.B4 
and mAb 3F4 (in black) with human cells of lymphoblastoid, 
myeloid and neuronal origin are shown in respect to an irrel-
evant phage antibody, specific for glucose oxidase, or to an 
IgG2b isotype control (solid line).
PBMC THP1 SK-N-BE PBMBMC Biotechnology 2007, 7:38 http://www.biomedcentral.com/1472-6750/7/38
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directed primarily against PrPc and do not selectively tar-
get the disease-associated prion protein. Hence, the pros-
pect of immunotherapy against prion diseases has
received considerable attention in recent years [20]. To
this regard, mAbs specifically recognizing prion protein
epitopes expressed on the cell surface of lymphoblastoid
cells may represent a valuable reagent for developing anti
TSE's therapies. The administration of rodent monoclonal
antibodies generated via hybridoma technology [21]
while feasible and effective presents several limitations:
for example the severe adverse effects due to its xenogenic
origin. For these reasons rodent monoclonal antibodies
require a technically challenging and expensive genetic
manipulation to generate chimeric and/or humanized
mAbs [7]. Recombinant antibody fragments, for example
scFv antibodies may represent an effective alternative. The
antibody fragments retain the targeting specificity of
whole mAbs but can be produced more economically and
possess other unique and superior properties for diagnos-
tic and therapeutic applications [11].
Data here reported and discussed indicated that the phage
antibodies isolated and characterized by us, represent use-
ful reagents for structure/function studies of the PrPc mol-
ecule and for developing an immunotherapeutic strategy
against prion disease. Furthermore, the genes encoding
for the scfvs MA3.B4 and MA3.G3 antibodies have been
isolated and sequenced, thus facilitating the delivery of
scFvs by genetic transduction in vivo for sustained produc-
tion of scFvs at predefined sites for prolonged periods of
time [9].
Methods
Prion proteins
Recombinant hamster prion protein, corresponding to
the mature form of hamster PrP containing five octare-
peats, has been purchased from Prionics AG (Zurich, Swit-
zerland). Homogenates from health hamster were
prepared starting from about 2 grams of brain tissue dis-
rupted in a Dounce homogenizer with 9 volumes of PBS/
0.5 % Nonidet P-40/0.5 % sodium deoxycholate. Insolu-
ble debris was removed by centrifugation at 1650 rpm for
20 minutes at 4°C. The supernatants were aliquoted and
stored at -80°C.
ETH-2 library
The ETH-2 synthetic human recombinant antibodies
library consists of a large array (more than 109 antibody
combination) of scFv polypeptides displayed on the sur-
face of M13 phage. It was built by random mutagenesis of
the CDR3 of only three antibody germline gene segments
(DP47 for the heavy chain, DPK22 and DPL16 for the
light chain). Diversity of the heavy chain was created by
randomizing four to six positions replacing the pre-exist-
ing positions 95 to 98 of the CDR3. The diversity of the
light chain was created by randomizing six positions (96
to 101) in the CDR3 [22].
Selection of prion protein specific phage antibodies from 
ETH-2 library
Immunotubes were coated overnight (ON) at room tem-
perature (RT) with rHaPrP in PBS at the concentration of
10  µg/ml. After panning, performed according with
Ascione et al. [12] phages were eluted with 1 ml of 100
mM triethylamine and the solution was immediately neu-
tralized by adding 0.5 ml of 1 M Tris-HCl pH 7.4. Eluted
phages were used to infect log phase TG1 E. coli bacteria
and amplified for the next round of panning. Briefly, 50
ml of 2xTY with 100 µg/ml ampicillin and 1% glucose
(2xTY-amp-glu) were inoculated with enough bacterial
suspension to yield an OD600 nm≅ 0.05–0.1. The culture
was grown to OD600 nm 0.4–0.5 and infected with K07
helper phage in a ratio of around 20 : 1 phage/bacteria.
The rescued phages were concentrated by precipitation
with PEG 6000 and used for next round of panning. For
monoclonal phage antibodies preparation, individual
TG1 bacterial colonies harbouring phagemides were inoc-
ulated in 150 µl 2xTY-amp-glu in 96 well plates, incu-
bated for 2 hours at 37°C and reinfected with 109 cfu K07
helper phage in 25 µl 2xTY. After 30 minutes, plates were
centrifuged at 1800 g for 10 minutes and bacterial pellet
resuspended in 200 µl 2xTY with 100 µg/ml ampicillin
and 25 µg/ml kanamycin (2xTY-amp-kan). The following
day the plates were spinned at 1800 g for 10 minutes and
the supernatants containing phage antibody were recov-
ered and tested in ELISA.
ELISA
96 well ELISA-plates were coated ON with 0.5 µg of
rHaPrP in PBS or 5 µl of homogenated brain extracts
(from healthy hamsters) diluted in 50 µl of PBS ON at RT.
Next day a blocking solution consisting of PBS with 2%
non-fat dry milk (2% MPBS) was added; plates were
washed with PBS containing 0.05% Tween 20 (TPBS) and
incubated for 1 hour at RT with phage supernatants. Plates
were washed and incubated for 1 hour with HRP mouse
anti-phage antibody (Amersham) resuspended in 2%
MPBS. The reaction was developed using 3,31-5,51-
tetramethylbenzidin BM blue, POD-substrate soluble
(Roche Diagnostics; IN, USA) and stopped by adding 50
µl of 1 M sulfidric acid. The reaction was detected with an
ELISA reader (BIORAD; CA, USA), and the results were
expressed as A (absorbance) = A(450 nm)-A(620 nm).
Cells
CCRF-CEM is a human T acute lymphoblastic leukaemia
cell line. Jurkat is a human T acute leukemia cell line.
RPMI 8226 is a human B Myeloma cell line. Nalm-6 is a
human pre-B acute lymphoblastic leukemia cell line.
HL60 is a human, acute promyelocytic leukemia, cell line.BMC Biotechnology 2007, 7:38 http://www.biomedcentral.com/1472-6750/7/38
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THP1 is a human, acute monocytic leukemia, cell line. H9
is a human T acute lymphoblastic leukemia cell line. SK-
N-BE is a human neuroblastoma cell line.
Cells were cultured in RPMI-1640 supplemented with
10% foetal calf serum (FCS), L-glutamine (2 mM) penicil-
lin (100 U/mL) and streptomycin (100 U/mL), all of
which were purchased from Hyclone (Logan, UT). Regu-
lation of prion protein expression in HL60 cell line was
induced by culture in 1 µmol ATRA (Sigma) for 1 and 3
days. Cells were then stained for flow cytometry.
PBMC were separated from heparinized venous blood
from healthy donors by centrifugation (20 min, 600 g)
over Ficoll (Gibco) and activated by phytohemagglutinin
P (PHA-P, 1 µg/ml, Sigma) for 4 days that stimulates T
lymphocytes.
Flow cytometry determination of PrPc
The expression of PrPc on cells surface was determined by
flow-cytometry studies. Cells in exponential phase of
growth were collected, extensively washed in PBS and pel-
letted. About 5 × 105 cells were resuspended with 50 µl 2%
MPB containing ≈ 1012 cfu phage particles and incubated
for 1 hour RT. After several washings cells were resus-
pended for 1/2 hour RT in 2% MPBS solution containing
10  µg/ml of mouse M13 secondary antibody (Amer-
sham), and after washings, cells were again incubated
with 6 µg/ml FITC-goat anti mouse Ig (Pierce, IL USA) for
1/2 hour at 4°C. Controls include irrelevant phage anti-
bodies directed to glucose oxidase and to tetanus toxin, an
IgG2b isotype control and mAb 3F4 (Dako).
After staining cell samples were washed, maintained at
4°C and immediately analyzed by FACS can (Becton-
Dickinson, NJ USA) equipped with 15 nW argon laser.
Fluorescence compensation was determined using sam-
ples stained with mouse M13 and FITC-conjugated goat
anti mouse secondary antibodies.
All experiments were done at least two times.
Immunocytochemistry
For cytospin preparation, 3 × 105 CCRF-CEM cells for slide
were spinned at 600 rpm in cytospeen 3 Shandom centri-
fuge (Pittsburgh PA USA) for 5 minutes and immediately
immersed in 80 % methanol solution for 10 minutes at
4°C. After three 5 minutes washes, in TBS, the slides were
treated for ten minutes with peroxidase block solution
from Dako En Vision system HRP (AEC), washed and
blocked with RPMI and 10% FCS (both from Hyclone
Laboratories) 10 minutes. The slides were incubated for 1
hour at RT in presence of 1011 cfu phage particles, exten-
sively washed and incubated with mouse M13 secondary
antibody (Amersham) for 1 hour RT. Finally treated with
labelled polymer solution 30 minutes, and then with AEC
substrate cromogen both belonging to the KIT. The coun-
ter stain was performed with mayer haematoxylin. Each
incubation was followed by three washes in TBS.
DNA characterization and sequences
Plasmid DNA from individual bacterial colonies of
MA3.B4 and MA3.G3 clones was digested with specific
endonucleases and CDR3 regions were sequenced with an
automated DNA sequencer (M-Medical/Genenco,
Pomezia Italy) using fdseq1 (5'-GAA TTT TCT GTA TGA
GG-3') and pelBback (5'-AGC CGC TGG ATT GTT ATT
AC-3') primers.
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